Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiora Pharmaceuticals (KPRX) FCF Margin (2016 - 2024)

Kiora Pharmaceuticals (KPRX) has disclosed FCF Margin for 8 consecutive years, with 18667.2% as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, FCF Margin changed N/A year-over-year to 18667.2%, compared with a TTM value of 38624.54% through Mar 2025, down 3866915.0%, and an annual FY2024 reading of 53.39%, changed N/A over the prior year.
  • FCF Margin was 18667.2% for Q2 2024 at Kiora Pharmaceuticals, down from 85.16% in the prior quarter.
  • Across five years, FCF Margin topped out at 383115.16% in Q1 2021 and bottomed at 18667.2% in Q2 2024.
  • Average FCF Margin over 3 years is 94118.62%, with a median of 35372.54% recorded in 2021.
  • Peak annual rise in FCF Margin hit 8483578bps in 2021, while the deepest fall reached 8483578bps in 2021.
  • Year by year, FCF Margin stood at 14175.86% in 2020, then soared by 598bps to 70659.92% in 2021, then tumbled by -126bps to 18667.2% in 2024.
  • Business Quant data shows FCF Margin for KPRX at 18667.2% in Q2 2024, 85.16% in Q1 2024, and 70659.92% in Q4 2021.